Oral PDE5 Inhibitors rarely cause priapism, finds study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2020-07-17 04:56 GMT   |   Update On 2020-07-17 04:56 GMT
Advertisement

USA: Phosphodiesterase type 5 inhibitor (PDE5i)-induced priapism is a rare event, according to a recent study published in the Journal of Sexual Medicine. The study suggests that PDE5i-induced priapism occurs but is less common than suspected. Drug-induced priapism should be attributed to a wider spectrum of medications that can cause this condition.

Priapism is an adverse drug reaction (ADR) associated with phosphodiesterase type 5 inhibitors (PDE5is) in the treatment of erectile dysfunction.

Advertisement

Michael E. Rezaee and Martin S. Gross from Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA, conducted the study with an aim to identify the true data about PDE5i-associated priapism to properly counsel patients.

The researchers queried the U.S. Food and Drug Administration (FDA) Adverse Reporting System Public Dashboard to identify cases of drug-induced priapism among medications commonly associated with priapism. Then they carried out a systematic review and analysis of publications describing cases of drug-induced priapism.

The main outcome of this study was the incidence of PDE5i-induced priapism. 

Key findings of the study include:

  • The researchers found 411 cases of drug-induced priapism secondary to Viagra, Cialis, or Levitra reported to the Food and Drug Administration since 1998.
  • Compared with PDE5is, drug-induced priapism was 2.6 (n = 1,065) and 2.0 times (n = 817) more commonly reported for second-generation antipsychotics and the antidepressant/sleep aid trazodone, respectively.
  • A total of 240 manuscripts describing cases of drug-induced priapism in patients with non-sickle cell disease were identified. PDE5i-induced priapism accounted for only 2.9% (n = 7) of drug-induced priapism cases.
  • Second-generation antipsychotics (33.8%), a group of "other" medications (11.3%), and alpha-adrenergic antagonists (8.8%) accounted for the greatest percentage of published drug-induced priapism cases.

"Extensive counseling about priapism as an ADR for PDE5i for the routine treatment of erectile dysfunction is likely unnecessary," wrote the authors. 

"PDE5i-induced priapism is a rare event. Drug-induced priapism should be attributed to a wider spectrum of medications that can cause this condition," they concluded.

The study, "Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?" is published in the Journal of Sexual Medicine.

DOI: https://doi.org/10.1016/j.jsxm.2020.05.019

Tags:    
Article Source : Journal of Sexual Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News